|
May 20
|
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: American Express, Walmart, Amazon, The Goldman Sachs and Merck & Co
|
|
May 15
|
Top Stock Reports for Broadcom, Merck & Airbnb
|
|
May 15
|
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
|
|
May 14
|
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
|
|
May 14
|
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
|
|
May 13
|
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
|
|
May 13
|
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
|
|
May 10
|
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
|
|
May 9
|
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
|
|
May 9
|
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
|
|
May 9
|
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
|
|
May 8
|
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
|
|
May 8
|
Q1 2024 OPKO Health Inc Earnings Call
|
|
May 8
|
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
|
|
May 6
|
Gossamer sells rights to drug it hopes can rival a new Merck therapy
|
|
May 6
|
Merck First Quarter 2024 Earnings: Beats Expectations
|
|
May 3
|
Here's Why Merck (MRK) is a Strong Momentum Stock
|
|
May 2
|
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
|
|
May 1
|
15 Best Places to Retire in Florida That You’ve Never Heard Of
|
|
May 1
|
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|